Holoprosencephaly (HPE) is a structural brain anomaly characterized by failure of the forebrain to separate during early embryogenesis. Both genetic and environmental etiologies of HPE have been discovered over the last three decades. Traditionally, the genetic workup for HPE has been a karyotype, chromosomal microarray, and/or Sanger sequencing of select genes. The recent increased availability of next-generation sequencing has changed the molecular diagnostic landscape for HPE, associating new genes with this disorder such as FGFR1. We conducted a systematic review of the medical literature for the molecular testing of HPE for studies published in the last 20 years. We also queried known commercial diagnostic laboratories and used information on their websites to construct a list of available commercial testing. Our group released its first recommendations in 2010 and this update incorporates the technology shifts and gene discoveries over the last decade. These recommendations provide a guide for genetic diagnosis of HPE, which is paramount for patients and their families for prognosis, treatment, and genetic counseling. 
| I N TR ODU C TI ON
Holoprosencephaly (HPE) is a structural brain anomaly characterized by failure of the forebrain to separate during early embryogenesis. HPE spans a spectrum from alobar (no separation of the forebrain) to middle hemispheric variant type (partial separation). There is also a type of HPE termed microform where there are no brain malformations seen on neuroimaging, but facial characteristics typical of HPE are seen such as hypotelorism, single central maxillary incisor, retinal coloboma, or clefting (Kruszka, Hart, Hadley, Muenke, & Habal, 2015) . As HPE is a rare condition without available evidence-based testing guidelines, we have summarized lessons from our three decades of molecular testing experience for HPE. Our group released its first recommendations in 2010 (Pineda-Alvarez, Dubourg, David, Roessler, & Muenke, 2010) and this update incorporates the technology shifts and gene discoveries over the last decade. The availability of next-generation sequencing (NGS) has changed the molecular diagnostic landscape for HPE, allowing for interrogation of genes associated with HPE in large cohorts of patients (Dubourg et al., 2016) and associating new genes with this disorder, such as FGFR1 (Hong et al., 2016; Roessler, Hu, & Muenke, 2018; Simonis et al., 2013) .
| M ET HOD S
We conducted a systematic review of the medical literature for the molecular testing of HPE for studies published in the last 20 years. We searched PubMed, Embase, and Google Scholar using the search terms "holoprosencephaly," "genetic testing," "next-generation sequencing," "whole exome sequencing," "whole genome sequencing," and "chromosomal microarray." Journal articles included were case reports, cohort studies, expert consensus, and review studies. Additional studies were ascertained from reference lists in these studies. We also queried known commercial diagnostic laboratories and used information on their websites to construct a list of available commercial testing (Table 1) .
| RE S U L TS A ND T ES TI N G RE COM M E ND A TI ON S

| Clinical evaluation
Molecular testing begins with the clinician collecting detailed phenotype information and pursuing genetic/genomic testing based on these findings. Simply ordering an HPE panel (Table 1) may not evaluate for syndromic HPE types, which make up over one half of all HPE cases . And as noted above, a pathogenic variant for HPE may not present with a brain anomaly, but as microform HPE (single central maxillary incisor, retinal coloboma, cleft palate/lip, hypotelorism, or microcephaly) (Kruszka et al., 2015) . Additionally, it is not uncommon for members of the same family carrying the same variant to present very differently (Kruszka et al., 2015; Stokes et al., 2017) .
Thus, variable expression and incomplete penetrance in HPE can make diagnosis difficult. Once a clinical diagnosis of HPE spectrum is made, the molecular testing pathway (Figure 1 ) is relatively simple and straightforward.
| Karyotype
In the absence of known family mutations, the first test ordered after either a prenatal or postnatal diagnosis of HPE is a karyotype. Given that over half of all cases of HPE are related to aneuploidy (Kagan, Staboulidou, Syngelaki, Cruz, & Nicolaides, 2010) , especially trisomy 13, a karyotype should be the first test. Aneuploidy can also be evaluated with chromosomal microarray and recently NGS (de Ligt et al., 2013; Li et al., 2014; Noll et al., 2016) ; however, these technologies in their current state may not be able to find structural anomalies such as balanced translocations. A review of chromosomal disorders is reviewed by Kruszka and Muenke (2018) in this issue.
| Microdeletion testing
In patients with a normal karyotype, genes known to cause HPE (see below) should be evaluated for deletions or duplications by one of the many available assays, such as microarray or multiplex ligationdependent probe amplification. Deletion/duplication testing is available on most commercial HPE testing panels (Table 1) . Single-gene or multigene deletions account for a significant fraction of HPE etiologies (Bendavid, Dubourg, et al., 2006; Bendavid, Haddad, et al., 2006; Stokes et al., 2017) . Bendavid et al. (2006) found that in cases with a normal karyotype and a normal screen for variants in SHH, TGIF1, SIX3, and ZIC2, 16 of 339 patients (4.7%) had a deletion in one of these genes. In another study evaluating fetuses with HPE and normal karyotypes, 13 of 94 (8.5%) fetuses had microdeletions involving SHH, TGIF1, SIX3, or ZIC2 (Bendavid et al., 2006) . If a pathogenic deletion is found in a proband, the parents should also be tested as there are multiple reports of microdeletion inheritance (Stokes et al., 2017) .
| Single-gene testing
HPE is a genetically heterogeneous condition with many implicated genes. Traditionally, testing for HPE single-gene variants has focused on Sanger sequencing technology. Recently, NGS has become part of clinical diagnostic practice, allowing for the simultaneous sequencing of multiple genes or entire genomes (Table 1) . Current NGS capture technologies have problems sequencing complete coding regions and are sensitive to guanine-cytosine content (Meienberg, Bruggmann, Oexle, & Matyas, 2016) . Certainly, as technology advances, especially to whole genome sequencing, capture issues will be resolved. Although, HPE research and NGS is beyond the scope of this guideline, Roessler et al. (2018) reviews genomic research in HPE in this issue. We have attached our Sanger sequencing procedure and primers for the genes SHH, SIX3, ZIC2, and TGIF1 (Supporting Information Tables I and II) that have been optimized for GC areas of genes. As noted above, NGS can also be used to evaluate for copy number variations (de Ligt et al., 2013; Li et al., 2014; Noll et al., 2016) . Gene panels sequenced at high read depths are particularly valuable at detecting small exon deletions that will be missed with chromosomal microarray (de Ligt et al., 2013) .
The most common and consistent genes associated with HPE are SHH, ZIC2, and SIX3. This has been supported by Dubourg et al. (2016) in an analysis of 257 patients with HPE that used an NGS panel and found the top genes associated with HPE to be SHH (5.8%), ZIC2
(1.2%), DLL1 (1.2%), and SUFU (0.4%). Many genes that are typically evaluated in HPE panels have not been associated with the classic forebrain malformations of HPE. Some of these genes are associated instead with "HPE-like" phenotypes where there are facial anomalies similar to those found in HPE or midline brain malformations that do not involve the cerebral hemispheres. Below, we review 18 genes that have been associated with HPE or HPE-like disorders and are available on commercial panels (Table 1) . Based on the clinical presentation of the patient, any one of these genes may be appropriate for testing.
Many of the genes below are members of three pathways implicated in HPE including the Shh signaling pathway, the Nodal signaling pathway, and the Bmp signaling pathway (Geng & Oliver, 2009 ). Based on the clinical presentation of the patient, any one of these genes may be appropriate for testing.
| SHH, SIX3, ZIC2, and TGIF1
Based on our experience and review of the medical literature, SHH, SIX3, and ZIC2 variants are most commonly associated with HPE. In 200 HPE cases (fetuses and children) with normal karyotypes, 34 (17%) had variants in SHH, SIX3, ZIC2, and TGIF1, with SHH variants being most common, occurring in 13 of the 17 (76%) (Dubourg et al., 2004) .
In another study of fetuses, children and adults with children, 21 variants in 86 cases (24%) were found to have variants in SHH, SIX3, ZIC2 (Paulussen et al., 2010) . Although TGIF1 has been associated with HPE and TGIF1 is on most HPE testing panels (Table 1) , variants in this gene are rare (Gripp et al., 2000; Keaton et al., 2010) . TGIF1 variants were not in the top 10 genes associated with HPE in the Dubourg et al.
study of 257 patients. About 10% of all patients with partial monosomy 18p, including deletion of the entire TGIF1 locus, manifest HPE, which
indicates that monoallelic mutations in this gene may contribute to pathogenicity, but are not sufficient to cause HPE (Roessler & Muenke, 1998; Turleau, 2008) . Interesting, variants in SHH, ZIC2, and SIX3 are distributed throughout all domains of these genes, see Figure 1 in this issue of Roessler et al. (2018) .
| GLI2
More recently, it has become clear that mutations in GLI2 do not tend to result in frank HPE, but instead cause a distinct phenotype that 
| DISP1
DISP1 is of great interest as it is part of the sonic hedgehog signaling pathway; however, multiple microdeletions and truncating variants involving DISP1 have failed to show brain malformations consistent with HPE (Roessler, Ma, et al., 2009; Roessler & Muenke, 1998; Shaffer et al., 2007) . Roessler et al. (2009) p.Ala248Val) in an adult with lobar HPE who inherited this variant from an unaffected mother (Weiss et al., 2018) .
| NODAL
Roessler et al. evaluated approximately 400 patients with HPE for variants in NODAL and found common variants in two individuals, p.H165R (rs1904589) and p.R302C (rs150819707), with ExAC allele frequencies of 62% and 0.06%, respectively (Lek et al., 2016; Roessler, Pei, et al., 2009 ). Remarkably, Roessler et al. (2009) found that both of these common polymorphisms had greater than 50% reduced bioactivity when using a zebrafish/luciferase assay. Given the allele frequency of these variants, they are not driver mutations but may be modifiers. Dubourg et al. (2016) found no pathogenic variants in NODAL in their large interrogation of 257 patients.
| FOXH1
FOXH1 participates in the NODAL signaling pathway and therefore is of interest to HPE research. Variants in FOXH1 are not a commonly found in HPE (Dubourg et al., 2016) . Roessler et al. (2008) found multiple variants in FOXH1 associated with HPE and demonstrated decreased activity of the protein in zebrafish assays; however, there are no further reports in the literature linking FOXH1 and HPE.
| TDGF1
TDGF1, a member of the nodal signaling pathway, has been described in one patient with HPE (de la Cruz et al., 2002) . The TDGF1 variant reported in this case, p.P125L (rs121909501), was found in 18 of 121,398 alleles (no homozygotes) in the ExAC database (Lek et al., 2016) .
| PTCH1
PTCH1 is a receptor for SHH and acts to repress SHH signaling.
Although an attractive candidate for HPE, PTCH1 is not a commonly found variant in HPE (Dubourg et al., 2016) . Multiple individuals in two reports (Ming et al., 2002; Ribeiro, Murray, & Richieri-Costa, 2006) have associated PTCH1 variants with HPE.
| DLL1
Rarely associated with HPE, Delta-like 1 (DLL1) is a notch ligand and has been shown to be coexpressed with FGF8 in the developing chick forebrain and part of the FGF signaling pathway (Dupe et al., 2011) . Dupe et al. (2011) additionally reported four patients with HPE with microdeletions containing DLL1, and one individual with HPE with a 3 bp deletion inherited from an unaffected parent (Dubourg et al., 2016) .
| GAS1
Pineda-Alvarez et al. (2012) 
| GLI3
GLI3 variants have been associated Pallister-Hall syndrome, Greig cephalopolysyndactyly syndrome, and polydactyly (Biesecker, 2011; Kang, Graham, Olney, & Biesecker, 1997; Wild et al., 1997) . Although GLI3 is part of the SHH signaling pathway, we do not know of variants in GLI3
being associated with classic HPE.
| FGFR1
FGFR1 is associated with Hartsfield syndrome and HPE (Hong et al., 2016; . Dubourg et al. (2016) found 2.3% of the 257 patients with HPE had FGFR1 variants. In Roessler et al. (2018) of this issue, Figure 1 shows that the distribution of FGFR1 variants spans all domains.
| SUFU
Like the other genes that encode components of the SHH signaling pathway, SUFU is of interest to HPE research. As noted above, Dubourg et al. (2016) found 0.4% of their cohort to have variants in SUFU. To our knowledge, testing for SUFU is not commercially available (Table 1) .
| Possible autosomal recessive genes
A homozygous missense variant FGF8 was identified in a proband from a consanguineous family who presented with semilobar HPE (McCabe et al., 2011) . STIL is associated with autosomal recessive HPE in two unrelated consanguineous families (Kakar et al., 2015; Mouden et al., 2015) .
3.19 | The final step in testing: testing family members and genetic counseling
The final part of the molecular workup is testing family members when a pathogenic variant is discovered in HPE. Although, most HPE variants can have devastating effects, these variants are incompletely penetrant and there are numerous examples of unaffected family members who are mildly affect or not affected (Kruszka et al., 2015; Stokes et al., 2017) . Whether a positive or negative result, the results of the testing is complex and requires in-depth counseling. In this issue, Hadley, Kruszka, and Muenke (2018) discuss genetic counseling in HPE.
| SU M M A R Y
In this review, we provide a guide (Figure 1 ) for molecular testing for clinicians taking care of patients affected by HPE. There are a number of factors that affect a clinician's decision making in the molecular workup of HPE including ease and availability of commercial testing, evidence of pathogenicity of genetic variation, and the phenotype spectrum considered. In this review, we have addressed each of these aspects of testing. Starting with availability of testing (Table 1) , there are a number of commercial HPE testing panels available and this presents a starting point for molecular workup. Here we have provided a table of most available testing laboratories at the time of this publication. We have also emphasized that molecular testing begins with a detailed clinical examination and that these panels will not find an etiology in the majority of HPE cases, in contrast to a karyotype, which will provide a molecular diagnosis for over half of all HPE cases. Second, this review examines the evidence of pathogenicity for genes associated with HPE, and for many of the genes tested (Table 1 ) the evidence for a causal association with HPE is weak or nonexistent. Certainly, there is substantial evidence to support the testing for the common genes (SHH, SIX3, and ZIC2), but evidence is lagging in other genes.
And lastly, the phenotype must be considered carefully. There are a number of genes that are considered "HPE spectrum" but are not consistently associated with classic HPE. As an example, GLI2 is widely tested in HPE (Table 1) , but it is part of the spectrum and not classic HPE. Thus, many of the genes reviewed in this study may be important for phenotypes other than classic HPE.
The challenge with testing recommendations put forth in this article is that technology and genetic research change quickly. Testing for HPE is a moving target and more genes will be added to testing panels as gene discovery continues over the next few years. However, current NGS technology seems to consistently fail to capture certain chromosomal regions in genes such as SHH, SIX3, and ZIC2, making Sanger sequencing still the gold standard for complete coverage of coding regions in the routine HPE four-gene screening. This limitation may apply to other HPE genes as well. Rare variants in approximately 1,500
genes have be associated with diseases that affect brain development or embryonic development (Wright et al., 2015) , and we predict that many of these genes will be linked to HPE in the future. As more of the etiology of HPE is understood going forward, our patients and their families will benefit in receiving a genetic diagnosis in the form of prognosis, treatment, and genetic counseling. 
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